Originally, we were staining patient specimens with CD3-FITC / CD19-PE
as part of our CLL panel. When we began to incorporate 3-color
techniques into our protocols, we attempted to add CD19-PerCP to the
BD kappa-FITC/lambda-PE tube. Even though BD markets two CD19
clones conjugated to PerCP, both reagents were dim or even negative in
many patients who were CD19-PE positive. Now we make a cocktail of
BD's kappa/lambda with CD20-PerCP. Even though B CLL often
demonstrates dim CD20, we have had better luck with this combination in
attempting to demonstrate light chain restriction than using the
CD19-PerCP. In addition, this combination allows us to target the
aberrant dim CD20 cells in the presence of normal B cells. Incidently,
we run CD5-FITC / CD20-PE / CD45-PerCP in the CLL panel as well.
Good Luck!
Cathy Fritschi
Sentara Norfolk General Hospital
Norfolk, VA
![]() |
![]() |
![]() |
![]() |
![]() |
CD-ROM Vol 3 was produced by Monica M. Shively and other staff at the
Purdue University Cytometry Laboratories and distributed free of charge
as an educational service to the cytometry community.
If you have any comments please direct them to
Dr. J. Paul Robinson, Professor & Director,
PUCL, Purdue University, West Lafayette, IN 47907.
Phone: (765)-494-0757;
FAX(765) 494-0517;
Web